Theme: Epidemiology & Public Health Research Year: 2019
Background: Drug users (IVDUs) are far more likely to have viral hepatitis (mainly HCV) infection
than other patient groups and a major risk group also for transmission of HIV . The purpose of our
study is the epidemiological characteristics and the incidence of all types of hepatitis, HAV, HBV, HCV
and HIV infection markers in toxic substances monitored at our hepatological department in Hellas.
Description of model of care/intervention: In our study were included all toxic substance users who
came to our department in 2017-2018. (N = 325, Men / Women = 217/108, mean age = 30.5 years,
range 21-58). All patients were tested for anti-HAV (IgG / IgM), HbsAg, anti-Hbc (IgG / IgM), HbeAg,
anti-HBs, anti-Hbe / HbeAg, anti-HCV and anti-HIV. All with positive anti-HCV were, afterwards,
tested by PCR HCV-RNA and genotype was determined.
Effectiveness: A total of 315 of the 325 subjects underwent complete serological screening. HbsAg
was detected in 15 of 315 subjects (4.16%), anti-Hbc (+) was detected in 87 out of 315 subjects
(27.62%), anti-Hbs in 62 out of 315 (19.68%) , anti-Hbe in 38 out of 315 individuals (12.1%), anti-HAV
IgG in 76 out of 315 (24.1%) and only 5 out of 315 (1.6%) were HIV-positive. Anti-HCV (+) was
detected in 255 of 315 (81%) and 174 (62.2%) of the 255 tested by PCR HCV-RNA was positive. The
genotype of the HCV infection was: GT1a = 15 (8.6%), GT1b = 18 (10.3%), GT2 = 4 (2.3%), GT3 = 111
(63.2%), GT4 = (14.9%).
4.16%
27.62%
19.68%
12.10%
24.10%
1.60%
81%
0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00% 90.00%
HBsAg
anti-Hbc
anti-Hbs
anti-Hbe
HAV
HIV
HCV
Conclusion and next steps: In our study, we have seen the high incidence of HCV infection in drug
users (IVDU) as reported in the international bibliography, while the incidence of HBV and HIV
infection is low. Concerning the genotypes of HCV infection, there was a significant increase in
genotypes 1 and 4 in our patients in Hellas.
Disclosure of Interest Statement: See example below: The conference collaborators recognise the
considerable contribution that industry partners make to professional and research activities. We
also recognise the need for transparency of disclosure of potential conflicts of interest by
acknowledging these relationships in publications and presentations.
Note: If accepted into the programme you will be requested to include a disclosure of interest slide
into your presentation or include such statements in your poster.